Invesco Biotechnology & Genome ETF
PBE
73 hedge funds and large institutions have $51M invested in Invesco Biotechnology & Genome ETF in 2016 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 24 reducing their positions, and 10 closing their positions.
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
3% more funds holding
Funds holding: 71 → 73 (+2)
2.64% less ownership
Funds ownership: 23.47% → 20.82% (-2.6%)
17% less capital invested
Capital invested by funds: $61.8M → $51M (-$10.8M)
42% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 24
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$2.69M |
| 2 |
NDSI
Newman Dignan & Sheerar Inc
Providence,
Rhode Island
|
+$663K |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$593K |
| 4 |
Stifel Financial
St. Louis,
Missouri
|
+$489K |
| 5 |
Jane Street
New York
|
+$326K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAM
Trillium Asset Management
Boston,
Massachusetts
|
-$4.32M |
| 2 |
LPL Financial
San Diego,
California
|
-$3.23M |
| 3 |
VF
Virtu Financial
New York
|
-$1.28M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$1.26M |
| 5 |
Morgan Stanley
New York
|
-$900K |
PBE Hedge Fund Activity: Q2 2016 in Review
73 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q2 2016, worth a combined $51M — down 17% from $61.8M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new PBE positions and 10 closed out — a net gain of 2 holders — while 14 added to existing stakes and 24 trimmed.
The largest buyer was Bank of America, adding an estimated $2.69M. The largest seller was Trillium Asset Management, cutting an estimated $4.32M.
- 73 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q2 2016, up from 71 in Q1 2016.
- Funds reported $51M of Invesco Biotechnology & Genome ETF stock for Q2 2016, down 17% quarter-over-quarter.
- 12 funds opened new Invesco Biotechnology & Genome ETF positions in Q2 2016 and 10 closed out, a net change of +2 holders.
- The largest Invesco Biotechnology & Genome ETF buyer in Q2 2016 was Bank of America, an estimated $2.69M added.
- The largest Invesco Biotechnology & Genome ETF seller in Q2 2016 was Trillium Asset Management, an estimated $4.32M sold.
Based on aggregated 13F filings for Q2 2016.